RPRX up +10.50% percent Today $RPRX High is at 10.53 and

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 12:35 PM

RPRX up +10.50% percent Today $RPRX High is at 10.53 and the Low 9.63 with current volume of 425,142.

Recent News posted below.

Repros Therapeutics Inc RPRX other info.
http://investorshangout.com/Repros-Therapeuti...PRX-55325/

RPRX Repros Therapeutics Inc Recent Headline News

Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
CLUB: 5.88 (-0.09), HYGS: 14.52 (-0.71), KNDI: 13.38 (-1.37), MCEP: 16.76 (+0.23), HYG.TO: 16.53 (-0.65), RPRX: 10.27 (+0.84), SHLD: 38.16 (+0.40), PAA.TO: 10.86 (+0.16), PAAS: 9.55 (+0.08), REXX: 7.27 (-0.28), AKBA: 11.42 (-0.79), GCBC: 25.32 (-2.40), ASEI: 44.52 (-0.25), MTEX: 23.05 (+0.27), PLNR: 6.90 (-0.25)

Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:20PM CST
Shares of Repros Therapeutics (RPRX) shot up 56.9% following a successful meeting with the FDA regarding Androxal.
BIIB: 317.81 (-3.21), RPRX: 10.27 (+0.84), ABBV: 63.93 (+0.17), AMAG: 34.65 (-0.28)

Repros Therapeutics posts 3Q loss
Automated Insights - Mon Nov 10, 8:13AM CST
WOODLANDS, Texas (AP) _ Repros Therapeutics Inc. (RPRX) on Monday reported a loss of $7.4 million, or 32 cents per share, in its third quarter.
RPRX: 10.27 (+0.84)

Repros Therapeutics beats by $0.07
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:11AM CST

RPRX: 10.27 (+0.84)

Repros Therapeutics Inc.(R) Reports Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 10, 8:00AM CST
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2014.
RPRX: 10.27 (+0.84)

Sears Soars Nearly +40% As REIT News Boosts Confidence
at The Street - Fri Nov 07, 2:42PM CST
Repros Therapeutics Inc (NASDAQ:RPRX), Sears Holdings Corp (NASDAQ:SHLD) and Allied Nevada Gold Corp. (NYSEMKT:ANV) are among the top-gaining billionaire stock picks of the day. On the losing end ar...
ANV: 1.20 (+0.07), AMSC: 1.01 (-0.07), RPRX: 10.27 (+0.84), SHLD: 38.16 (+0.40), STAY: 17.62 (-0.01)

Midday Gainers/Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 11:52AM CST

ROKA: 3.53 (-0.06), NES: 7.98 (-0.19), FNGN: 32.32 (+0.04), FIVN: 4.97 (+0.06), MSON: 12.17 (+0.17), SLXP: 96.04 (+0.49), SUMR: 2.87 (+0.07), RPRX: 10.27 (+0.84), QTWO: 18.00 (+0.09), EV: 41.13 (-0.27), SHLD: 38.16 (+0.40), STAY: 17.62 (-0.01), PSIX: 68.30 (-1.55), BORN: 1.49 (-0.01), URRE: 2.26 (-0.23), ECOM: 18.58 (-0.18), ICPT: 155.87 (-7.09), SAEX: 3.88 (-0.14), VPCO: 1.88 (+0.31), SZYM: 3.47 (-0.05)

Repros Therapeutics (RPRX) Stock Skyrockets After Meeting with FDA About Androxal
at The Street - Fri Nov 07, 10:07AM CST
Shares of Repros Therapeutics (RPRX) soared in morning trading Friday after the biopharmaceutical company held what it called a "constructive meeting" with the FDA regarding its testosterone-boosting drug Androxal.
RPRX: 10.27 (+0.84)

Repros jumps after FDA meeting on Androxal NDA
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 9:20AM CST

RPRX: 10.27 (+0.84)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST

BEBE: 2.43 (-0.04), ANET: 77.37 (+0.13), TKMR: 16.43 (+0.33), ORBC: 6.40 (-0.17), MDRX: 12.38 (+0.43), RMTI: 11.02 (-0.22), CTIC: 2.18 (unch), SHLD: 38.16 (+0.40), UBNT: 28.51 (-0.49), RIG: 26.27 (-0.81), KGC: 2.53 (+0.07), APT: 2.87 (-0.13), ANF: 29.17 (-0.18), MITK: 3.49 (-0.17), ZNGA: 2.80 (-0.01), CNET: 2.08 (-0.07), KING: 15.43 (+1.40), NETE: 1.38 (-0.02), SLXP: 96.04 (+0.49), RPRX: 10.27 (+0.84), NADL: 4.30 (-0.64), PGNX: 6.64 (+0.03), AVNR: 13.27 (+0.09), FSLR: 47.93 (-1.66), DVA: 76.83 (+0.11), NDLS: 23.72 (-0.42), ICPT: 155.87 (-7.09), AGIO: 86.22 (-0.65), PLNR: 6.90 (-0.25)

Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing
GlobeNewswire - Thu Nov 06, 3:21PM CST
-- No New Clinical Studies Requested
RPRX: 10.27 (+0.84)

Will Repros (RPRX) Miss Estimates This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:12PM CST
Repros Therapeutics Inc. (RPRX) has an earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 87.30 (-5.69), PBH: 31.65 (-0.14), RPRX: 10.27 (+0.84), HSP: 57.79 (-0.30)

63.7% Return Seen to Date on SmarTrend Repros Therapeutics Call (RPRX)
Comtex SmarTrend(R) - Mon Nov 03, 10:56AM CST
SmarTrend identified a Downtrend for Repros Therapeutics (NASDAQ:RPRX) on September 4th, 2014 at $17.86. In approximately 2 months, Repros Therapeutics has returned 63.72% as of today's recent price of $6.48.
RPRX: 10.27 (+0.84)

Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 7.04 (+0.09), PTX: 11.00 (-0.05), AKRX: 37.27 (+1.84), RPRX: 10.27 (+0.84), NKTR: 13.91 (-0.06)

Repros to Webcast Investor and Analyst Day on October 31st
GlobeNewswire - Mon Oct 27, 3:01PM CDT
Repros Therapeutics Inc.(Nasdaq:RPRX) today announced that it will host a live webcast of its Investor and Analyst Day that is being held in New York City on Friday, October 31, 2014 beginning at 7:30 a.m. Eastern Time.
RPRX: 10.27 (+0.84)

Biotech Stock Roundup: AbbVie Calls off Shire Acquisition, Will Amgen Consider Breakup? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 22, 10:18AM CDT
Will Amgen (AMGN) go the Abbott (ABT) way and split into two separate companies?
PCYC: 138.43 (+1.06), NPSP: 29.38 (+0.21), RPRX: 10.27 (+0.84), AMGN: 160.52 (-1.41), ABBV: 63.93 (+0.17), REGN: 399.26 (-1.85), CELG: 106.95 (-1.30)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Pathalys' Phase 3 Data Shows Promise for CKD Drug

A Glimpse at Pathalys Pharma's Recent Win This is some groundbreaking stuff emerging from Pathalys Pharma. Their investigational drug, upacicalcet, has just clinched a significant victory in two crucial Phase 3 trials - PATH-1 and PATH-2 - aimed at treating Secondary Hyperparathyroidism (SHPT) in patients with end-stage kidney disease undergoing hemodialysis. With SHPT...

CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

World Young Scientist Summit 2026 in Wenzhou Kicks Off

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

DIRECTV Bags New NHL Deals: Stakes for Sports Fans

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Apalutamide Boosts Outlook for Prostate Cancer Treatment

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

John Wong's Decade as Estate Planning Specialist

One man's legacy isn’t built overnight, especially not in estate planning. And John L. Wong's decade of being a certified specialist by the State Bar of California tells a story of perseverance and grit. Now, at the helm of Modern Wealth Law in Irvine, California, Wong is a name that echoes through the halls of estate planning law with authority and respect. Creating...

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...